CompletedNCT00650429
Injected then oral ziprasidone for acute schizophrenia or schizoaffective symptoms
About this title
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Read the official source — NCT00650429Medication studyAges 18–70Mexico
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- Monterrey and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 28
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Mexico
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00650429
- Official title
Show the full official title
Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study
Get this study by email
Recruitment & locations
CompletedMonterrey · DF · Mexico City
1 more locations
- Mexico D F
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone.
Who was this study for?
Listed age limits: 18 years to 70 years.
Want to explore more studies?
Explore studiesRelated studies
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA